8-19962213-C-G
Variant summary
The NM_000237.3(LPL):c.1421C>G (p.Ser474*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. This is a loss-of-function variant that does not trigger NMD. The gene LPL is a tumor suppressor gene (CancerMine: 2 TSG, 6 oncogene, 2 driver citations). The gene LPL is a known oncogene (CancerMine: 2 TSG, 6 oncogene, 2 driver citations). The gene LPL is a cancer driver gene (CancerMine: 2 TSG, 6 oncogene, 2 driver citations). The variant allele was found at a cumulative frequency of 0.0968 (AC=156,015) in the gnomAD database across 1,611,322 control chromosomes, including 7,879 homozygotes. The grpmax filtering allele frequency (95% CI) is 0.119. In-silico predictor (BayesDel (noAF)) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign/Likely Benign (★★). The variant has been observed in cBioPortal in 3 samples across 2 studies and 3 cancer types; somatic enrichment level: SUPPORTING_LOW (Observed in a small number of cBioPortal cases.).
Frequency
Consequence
NM_000237.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- familial lipoprotein lipase deficiencyInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Laboratory for Molecular Medicine, Genomics England PanelApp, Natera, Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
- hyperlipidemia, familial combined, LPL relatedInheritance: AD, SD, Unknown Classification: STRONG, LIMITED Submitted by: Genomics England PanelApp, PanelApp Australia, Natera
Genome browser will be placed here
Classification according to ACGS-UK Somatic Oncogenicity v2025
Our verdict: Likely_benign. The variant received -2 points.
| Apply | Criterion Code & Title / Strength | Rationale / Clinical Context | |
|---|---|---|---|
| O2Null variant in tumour suppressor gene | Non-NMD frameshift: LoF oncogenic mechanism, end-terminal — O2 moderate (+2); Use caution in the presence of multiple transcripts; Gene confirmed as TSG in CancerMine (TSG: 2 citations, oncogene: 6 citations, driver: 2 citations).; Frameshift/stop-gained. NMD predicted: false. LoF mechanism: true. Downstream pathogenic count: 0. | ||
| B1High frequency in general population | GnomAD effective popmax AF >1% — B1 stand-alone benign; GnomAD effective popmax AF = 0.119 — exceeds 1% threshold (B1 applied) |
Variant Effect in Transcripts
Automated classification analysis was done for transcript: NM_000237.3. You can select a different transcript below to see updated classification assignments.
RefSeq Transcripts
Ensembl Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
LPL | MANE Select | c.1421C>G p.Ser474* | stop_gained | Exon 9 of 10 | Prot: ENSP00000497642.1 UniProt: | |
LPL | c.1421C>G p.Ser474* | stop_gained | Exon 11 of 12 | Prot: ENSP00000635987.1 UniProt: | ||
LPL | c.1418C>G p.Ser473* | stop_gained | Exon 9 of 10 | Prot: ENSP00000635988.1 UniProt: |
Frequencies
Allele frequencies (AF), counts (AC/AN), homozygotes and coverage
| Source / population | AF | AC | Hom | AN | Coverage |
|---|---|---|---|---|---|
Global population databases 6 sources | |||||
GnomAD3 genomes | AF: 0.0902 | AC:13720 | Hom:611 | AN:152082 | Cov:32 |
GnomAD2 exomes | AF: 0.0922 | AC:23148 | AN:251182 | ||
GnomAD4 exome | AF: 0.0975 | AC:142308 | Hom:7269 | AN:1459122 | Cov:31 |
GnomAD4 genome | AF: 0.0901 | AC:13707 | Hom:610 | AN:152200 | Cov:32 |
TOPMed (Bravo) | AF: 0.0879 | AC:23273 | Hom:1103 | AN:264690 | |
ALFA (dbGaP/dbSNP Allele Frequency Aggregator) | AF: 0.0990 | AC:12022 | Hom:621 | AN:121420 | |
Local & regional cohorts 11 sources | |||||
ABraOM SABE-WGS-1171 | AF: 0.0944 | AC:221 | Hom:15 | AN:2342 | |
ChinaMAP Phase 1 | AF: 0.0912 | ||||
Denmark Genome | AF: 0.120 | AC:36 | AN:300 | ||
ESP6500 (Exome Variant Server) | AF: 0.0863 | AC:1123 | AN:13006 | ||
GenomeAsia100K | AF: 0.100 | AC:346 | AN:3478 | ||
Korea4K (4,157 Koreans) | AF: 0.116 | AC:840 | AN:7234 | ||
Qatari Genome | AF: 0.0825 | AC:165 | AN:2000 | ||
ToMMo 61KJPN (+60KJPN MNV) | AF: 0.131 | AC:16028 | Hom:1040 | AN:122780 | |
Turkish Variome | AF: 0.104 | AC:698 | Hom:43 | AN:6708 | |
UK10K | AF: 0.107 | AC:811 | AN:7562 | ||
WBBC (Westlake BioBank for Chinese) pilot | AF: 0.102 | AC:917 | Hom:53 | AN:8960 | |
Case/control cohorts
| Cohort | Cases | Controls | ||||
|---|---|---|---|---|---|---|
| AF | AC | AN | AF | AC | AN | |
ASC | 0.0963 * | 1070 | 11108 | 0.100 * | 1768 | 17610 |
BipEx | 0.0976 | 2773 | 28420 | 0.0971 | 2802 | 28844 |
Epi25 | 0.101 | 4233 | 41946 | 0.0927 | 6170 | 66536 |
SCHEMA | 0.105 | 13524 | 128696 | 0.107 | 21829 | 203540 |
ClinVar
Computational Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
AlphaGenome AVI | Pathogenic | 46 | |
BayesDel_addAF | Pathogenic | 0.17 | D |
BayesDel_noAF | Pathogenic | 0.57 | |
CADD | Pathogenic | 46 | |
DANN | Uncertain | 1.0 | |
Eigen | Pathogenic | 0.99 | |
Eigen_PC | Pathogenic | 0.83 | |
FATHMM_MKL | Benign | 0.70 | D |
GPN-Star LLR | N/A | -9.4 | |
GPN-Star score | N/A | 9.4 | |
PhyloP100 | Benign | 0.43 |
Splicing Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
DS_DG_spliceai | Uncertain | 0.20 | Position offset: -3 |
Pangolin (max) | Uncertain | 0.23 | |
Pangolin loss | Uncertain | 0.23 | Position offset: 6 |
SpliceAI score (max) | Uncertain | 0.20 | Details are displayed if max score is > 0.2 |
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.